Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Adults - Recent Insights
Published: 2023-07-29
Page: 148-152
Issue: 2023 - Volume 6 [Issue 1]
Nikita Gupta *
Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telangana, India.
Swetha Singarapu
Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telangana, India.
Hema Pasupuleti
Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telangana, India.
Mohd Ilham Ahmed
Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telangana, India.
Sameera Fatima
Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telangana, India.
*Author to whom correspondence should be addressed.
Abstract
Ankylosing spondylitis, also called spine osteoarthritis, radiographic axial spondyloarthritis is a form of arthritis which is autoimmune in nature and leads to chronic spine inflammation including inflammation of the sacroiliac joint (situated in between the base of the vertebrae and the pelvis) leading to permanent disability in which patient will find difficulty in walking as well as breathing (as rib cage expands during breathing) and doing daily activities. Currently non-steroidal anti-inflammatory drugs (NSAIDs) and biological agents, including TNFα inhibitors and IL-17 inhibitors are considering as the treatment options. Despite the fact that these medications are available, many patients either do not respond well, slowly lose their initial therapeutic response, or experience unfavourable side effects, underscoring the need for alternative treatment approaches. Tofacitinib which is a janus kinase inhibitor, have more axial penetration than other FDA approved drugs for ankylosing spondylitis. As a result, it is crucial in blocking the process of intracellular signalling from the receptor to the cellular nucleus and blocks the inflammatory response through a novel pathway. In this review, we discuss the role of tofacitinib in axial spondyloarthritis (axSpA) and present the findings of current clinical trials of JAKi (tofacitinib, Upadacitinib, and filgotinib) in axSpA patients.
Keywords: Ankylosing spondylitis (AS), Axial spondyloarthritis (axSpA), autoimmune, immune mediated, tofacitib, Janus kinase (JAK) inhibitor (JAKi)
How to Cite
Downloads
References
Boel A, Molto A, van der Heijde D, et al. Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. Ann Rheum Dis. 2019;78:1545–9.
Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:137990.
Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology. 2014;53:650–7.
Sieperr J, Braun J, Rudwaleit M, et al. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;61(Suppl 3):8iii–18.
Poddubnyy D, Sieper J. Treatment of axial spondyloarthritis: what does the future hold? Curr Rheumatol Rep. 2020;22:47.
Bohn R, Cooney M, Deodhar A, et al. Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature. Clin Exp Rheumatol. 2018;36:263–74.
Michael Gibson C, Manpreet Kaur. Ankylosing spondylitis epidemiology and demographics Prof Jürgen Braun MD a, Prof Joachim Sieper MD,Ankylosing spondylitis. The Lancet. 369(9570):1319-1402
Lai-Shan Tam et al. Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol; 2010.
Davis JC, Van Der Heijde D, Braun J et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48:3230
Inkinen J, Sand J, Arvola P, Pörsti I, Nordback I. Direct effect of thyroxine on pig sphincter of Oddi contractility. Dig Dis Sci. 2001;46:182–186.
Davis JC, Van Der Heijde D, Braun J et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48:3230.
Braun J, Deodhar A, Inman RD et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis. 2012;71:6617.
Ritchlin CT. Therapeutic considerations in spondyloarthritis patients who fail tumour necrosis factor antagonists. Best Pract Res Clin Rheumatol. 2010;24:683-92.
Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186:4234–43.
Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010;7:41.
Changelian PS, Moshinsky D, Kuhn CF, et al. The specificity of JAK3 kinase inhibitors. Blood. 2008;111:2155–7.
Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. Arthritis Rheum. 2012;64:1790–8.
Sherlock JP, Cua DJ. Interleukin-23: a promising therapeutic target in seronegative spondyloarthropathy. Curr Opin Pharmacol. 2013;13:445–8.
Liu W, Wu YH, Zhang L, et al. Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis. Int J Clin Exp Med. 2015;8:17362–76.
Przepiera-Będzak H, Fischer K, Brzosko M. Serum IL-6 and IL-23 levels and their correlation with angiogenic cytokines and disease activity in ankylosing spondylitis, psoriatic arthritis, and SAPHO syndrome. Mediators Inflamm. 2015;2015:785705 [Epub ahead of print]
Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect. 2009;11:625–30.
Van der Heijde D, Deodhar A, Wei JC, et al. Ann Rheum Dis. 2017;76:1340–1347.
Eric Toussirot. The use of janus kinase inhibitors in axial spondyloarthritis: current insights. Pharmaceuticals. 2022;15:270.
Ogdie A, de Vlam K, McInnes IB, et al. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. RMD Open. 2020;6:e001042. DOI:10.1136/rmdopen-2019-001042
Lee YH. Comparative efficacy and safety of janus kinase inhibitors and secukinumab in patients with active ankylosing spondylitis: a systematic review and meta-analysis. Pharmacology. 2022;107(11-12):537-544.
DOI: 10.1159/000525627. Epub 2022 Jul 11. PMID: 35817017; PMCID: PMC9811419.
Maksymowych WP, Van Der Heijde D, Baraliakos X, Deodhar A, Sherlock SP, Li D, Fleishaker D, Hendrikx T, Kanik KS. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. Rheumatology (Oxford). 2018;57(8):1390-1399.
DOI: 29.1093/rheumatology/key104. PMID: 29718421; PMCID: PMC6055606.
Shu Li, Fen Li, Ni Mao, Jia Wang, Xi Xie. Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: A systematic review and meta-analysis. European Journal of Internal Medicine. 2022;102:47-53.
Lee YH. Comparative efficacy and safety of janus kinase inhibitors and secukinumab in patients with active ankylosing spondylitis: A systematic review and meta-analysis. Pharmacology. 2022 Jul 11;107(11-12):537-44.
Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, Wang L, Wu J, Menon S, Wang C, Dina O. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Annals of the rheumatic diseases. 2021 Aug 1;80(8):1004-13.